SAN JOSE, CA., Dec. 12, 2015 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSCelesta™ flow cytometer during the 2015 American Society for Cell Biology (ASCB) annual meeting. Uniquely designed to leverage the broad BD Horizon Brilliant™ reagent portfolio, this new system offers simultaneous measurement of up to 14 different single cell characteristics.
The BD FACSCelesta is an advanced system for driving scientific insights for a wide range of applications. Available now for research segment use, the BD FACSCelesta is the latest advancement in the award winning BD cell analyzer portfolio. It offers performance that is typically only seen in higher end systems, enabling consistency of results and seamless transfer of applications between BD platforms with 14 parameters in a three-laser benchtop system.
For more significant single cell studies and higher quality data, the BD FACSCelesta system opens new avenues of investigation and a deeper level of biological study. When combined with the patented technology of BD Horizon Brilliant™ polymer dyes, it enables greater resolution of previously unobserved cell populations and is an ideal solution for researchers wanting more fluorophore choices when using multicolor flow cytometry.
“Designed from the ground up, the BD FACSCelesta allows researchers to benefit from new innovations in instrument and reagent technology,” said Claude Dartiguelongue, worldwide president of BD Biosciences. “This means that researchers can now, with improved brightness and low spectral overlap, optimally identify, characterize, and resolve even dim staining populations of interest.”
The BD FACSCelesta flow cytometer is available in multiple configurations, delivering the performance required for varied immunology and cell biology applications. The system can help simplify experimental design and analysis for experienced researchers as well as those new to flow cytometry. The four configurations allow the use of 10 or 12 colors. The first live presentation will be held during the American Society for Cell Biology annual meeting held today through Dec. 16 at the San Diego Convention Center.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.